Philips’ image-guided navigation increases safety during coronary interventions and reduces the use of contrast media by an average of 28.8%
May 16, 2023
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3% 
Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking data from the DCR4Contrast (Dynamic Coronary Roadmap for Contrast Reduction) trial, the largest ever randomized controlled multicenter clinical trial to investigate the ability of Philips Dynamic Coronary Roadmap (DCR) to reduce the total iodinated contrast media volumes administered during percutaneous coronary intervention (PCI) procedures, compared to PCI performed without DCR guidance. The results were presented today at the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2023 course and will also be presented later this week at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 scientific sessions.
The number of high-risk patients undergoing PCI procedures worldwide has increased significantly . Iodine contrast media is used to visualize the coronary arteries during PCI procedures, but it can potentially harm the kidneys, risking the development of contrast-induced acute kidney injury (CI-AKI) after the procedure. The study found that Dynamic Coronary Roadmap reduced the total iodine contrast volume per procedure on average by 28.8% (95% Confidence Interval: 18.9%, 38.2%), and reduced the number of angiograms per procedure on average by three runs based on a procedure with an average of 11 runs or 26.3% reduction (95% Confidence Interval: 16.8%, 35.1%) .
“Enabling physicians to decrease contrast administration during procedures with tools like DCR could make a significant contribution to both the safety and quality of PCI. This is important at a time when PCI is increasingly used in patients with a complex clinical or anatomical profile,” said Prof. Javier Escaned, MD, Head of the Interventional Cardiology Section at Hospital Clinico San Carlos, Madrid Spain, who presented the results today during a late-breaking session at the annual meeting for the EuroPCR 2023 (May 16-19, Paris, France).
“At Philips, we are committed to championing technologies that improve the patient’s experience, improve their safety and expand access to procedures to new patient groups. Dynamic Coronary Roadmap helps achieve these goals by structurally reducing the amount of contrast agent required for PCI procedures,” said Dr. Atul Gupta, Chief Medical Officer for Image Guided Therapy at Philips.
Multi-center, prospective, unblinded, stratified, 1:1 randomized controlled trial
The DCR4Contrast trial ran from November 2019 to February 2023 across hospitals in the U.S., Europe and Israel. In total, 371 patients were randomized and stratified within both ad hoc and planned PCI, according to the number of vessels to be treated. Patients in the DCR group underwent PCI procedures where DCR was used to guide coronary wires, balloons, stents and other PCI diagnostic or therapeutic devices. Patients assigned to the control group underwent PCI without DCR support, following the current standard of care .
On Thursday, May 18 Professor John C. Messenger, MD, University of Colorado School of Medicine and Director of the Cardiac Catheterization Laboratories and Cardiovascular ICU at the University of Colorado Hospital will present the data at the Society for Cardiovascular Angiography & Interventions (SCAI): “These results are very exciting,” Professor Messenger commented. “They confirm that Philips Dynamic Coronary Roadmap can be applied to all PCIs and has the potential to increase overall PCI safety by mitigating one of the few preventable contributors (iodinated contrast media use) to contrast-induced acute kidney injury following PCI.” More information on Professor Messenger’s presentation at SCAI can be found here.
Philips’ Dynamic Coronary Roadmap software is a real-time visualization innovation that removes the need for additional contrast media injections by overlaying the angiogram onto real-time motion-compensated 2D fluoroscopic imaging to provide interventionalists with continuous visual feedback on the positioning of guide wires and catheters. Complementing this technology, the Philips IntraSight precision guidance system streamlines lesion assessment, simplifies vessel sizing, enables precise therapy delivery and also supports the operator in their goal to reduce contrast volumes.
 Study reference number DHF287327
 Waldo SW, Gokhale M, O’Donnell CI, Plomondon ME, Valle JA, Armstrong EJ, Schofield R, Fihn SD, Maddox TM. Temporal Trends in Coronary Angiography and Percutaneous Coronary Intervention: Insights From the VA Clinical Assessment, Reporting, and Tracking Program. JACC Cardiovasc Interv 2018;11:879–888.
For further information, please contact:
Philips Global Press Office
Tel: +31 6 10 55 8116
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Rovio Entertainment Corp.: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act7.6.2023 08:00:00 CEST | Press release
Rovio Entertainment Corporation Stock Exchange Release June 7, 2023 at 9.00 a.m. EEST Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act Rovio Entertainment Corporation (the "Company") has received a notification pursuant to Chapter 9, Section 5 of the Securities Markets Act from FMR LLC. According to the notification, the holding of FMR LLC in the Company's shares and votes decreased below the 5% threshold on June 5, 2023. Following the transaction, FMR LLC owns 4.85% of the Company’s shares and voting rights. Total positions of FMR LLC: % of shares and voting rights % of shares and voting rights through financial instruments Total of both in % Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached 4.85 0 4.85 82,963,825 Position of previous notification 5.69 0 5.69 Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shar
Completion of conversion of A shares to B shares in accordance with the articles of association and information on adjusted number of voting rights and share capital7.6.2023 07:38:16 CEST | Press release
Company announcement for ROCKWOOL A/S Release no. 9 – 2023 to Nasdaq Copenhagen 7 June 2023 Completion of conversion of A shares to B sharesin accordance with the articles of association and information onadjusted number of voting rights and share capital ROCKWOOL A/S has today completed the conversion of 67,503 A shares to a corresponding number of B shares (each having a nominal value of DKK 10). The conversion is effected in accordance with article 6 of the articles of association and at the request of the holders of the A shares in question. The company’s articles of association have been updated with the resulting changes to the size of the company’s A- and B share capital. The total share capital is unchanged. The articles of association can be found on the company’s website. In accordance with Section 32 of the Danish Capital Market Act, ROCKWOOL A/S is required to publish the total number of voting rights and the size of the share capital in the event of changes. Following the
Gennemførsel af vedtægtsbestemt omregistrering af A-aktier til B-aktier samt oplysning om ændret antal stemmerettigheder og kapital7.6.2023 07:38:16 CEST | pressemeddelelse
Selskabsmeddelelse for ROCKWOOL A/S Meddelelse nr. 9 – 2023 til Nasdaq Copenhagen 7. juni 2023 Gennemførsel afvedtægtsbestemt omregistrering af A-aktier til B-aktiersamt oplysning om ændret antal stemmerettigheder og kapital ROCKWOOL A/S har i dag gennemført omregistreringen af 67.503 A-aktier til et tilsvarende antal B-aktier (hver af nominelt kr. 10). Omregistreringen sker i henhold til vedtægternes § 6 og på anmodning fra ejerne af de pågældende A-aktier. Selskabets vedtægter er blevet opdateret med de deraf følgende ændringer af størrelsen af selskabets A- og B-aktiekapital. Den samlede selskabskapital er uændret. Vedtægterne kan findes på selskabets hjemmeside. I henhold til kapitalmarkedslovens § 32 er ROCKWOOL A/S forpligtet til at offentliggøre stemmerettigheder og aktiekapitalens størrelse i tilfælde af ændringer. ROCKWOOL A/S’ samlede antal stemmerettigheder og aktiekapital udgør (efter ændringen): AktiekapitalNominel værdiStemmerA-aktiekapitalDKK107.994.040107.994.040B-aktie
Danske Bank announces new, focused strategy for Norway7.6.2023 07:31:00 CEST | Press release
Company announcement no. 5 2023 Danske Bank A/S Holmens Kanal 2 – 12 DK - 1092 København K Tel. +45 45 14 00 00 7 June 2023 Danske Bank announces new, focused strategy for Norway Going forward, Danske Bank will focus on the business, large corporate and institutional segmentsin Norway and announcesplan to leave the Norwegian personal customer market. As part of Danske Bank’s new Forward ’28 strategy, we have decided to focus our business in Norway on the business, large corporate and institutional customers. These are customer segments in which Danske Bank has a strong position, have demonstrated solid performance and profitability over the past years and continue to see a large potential, as we do in our other Nordic markets. Danske Bank announces plan to leave the personal customers market in Norway In our Norwegian personal customer business, we have been making progress in recent years and today, we have a solid business with an attractive group of customers and highly skilled empl
Danske Bank offentliggør ny, fokuseret strategi for Norge7.6.2023 07:31:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 5 2023 Danske Bank A/S Holmens Kanal 2-12 1092 København K Telefon 45 14 14 00 7. juni 2023 Danske Bank offentliggør ny, fokuseret strategi for Norge Fremadrettet vil Danske Bank fokusere på erhvervskunder og institutionelle kunder i Norge og offentliggør plan for at forlade det norske privatkundemarked. Som en del af Danske Banks nye strategi Forward ’28 er det besluttet, at vi i Norge vil fokusere vores aktiviteter på erhvervs- og institutionelle kunder. Det er kundesegmenter, hvor Danske Bank har en stærk position, har skabt gode resultater og lønsomhed i de senere år og fortsat ser et stort potentiale, som det også er tilfældet på de andre nordiske markeder. Danske Bank offentliggør plan for at forlade det norske privatkundemarked Vi har i de senere år gjort fremskridt i den norske privatkundeforretning, og vi driver i dag en god forretning med en attraktiv kundegruppe og meget kompetente medarbejdere. Dog vil det kræve betydelige investeringer at styrke bank